MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-19-2026
DarioHealth Corp. Operating Income 2011-2026 | DRIO
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income DarioHealth Corp.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -36.7 M | -57.7 M | -56.2 M | -56.8 M | -76.5 M | -29.9 M | -17.7 M | -17.7 M | -14.4 M | -11.1 M | -7.7 M | -11.4 M | -13.6 M | -3.97 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -3.97 M | -76.5 M | -29.4 M |
Quarterly Operating Income DarioHealth Corp.
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -9.48 M | -9.2 M | -9.41 M | - | -12 M | -16.2 M | -17.9 M | - | -15.5 M | -14 M | -12.4 M | - | -14.6 M | -17.4 M | -15.9 M | - | -22.5 M | -18 M | -14.3 M | - | -6.6 M | -4.12 M | -10.1 M | - | -2.8 M | -5.36 M | -5.36 M | - | -4.05 M | -5.79 M | -2.92 M | - | -2.98 M | -4.12 M | -4.2 M | - | -2.72 M | -2.62 M | -1.92 M | - | -2.55 M | -1.51 M | -1.78 M | - | -2.51 M | -3.6 M | -2.67 M | - | -3.24 M | -3.6 M | -3.08 M | - | -1.02 M | -866 K | -495 K | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -495 K | -22.5 M | -7.41 M |
Operating Income of other stocks in the Diagnostics research industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Akumin
AKU
|
-28.1 M | - | -17.87 % | $ 25.9 M |  Canada |
|
Centogene N.V.
CNTG
|
-46 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Agilent Technologies
A
|
1.35 B | $ 114.87 | -0.65 % | $ 34.9 B |  USA |
 |
Accelerate Diagnostics
AXDX
|
-14 M | - | -61.36 % | $ 2.46 M | USA |
 |
Aspira Women's Health
AWH
|
-7.91 M | - | -6.19 % | $ 10.5 M | USA |
 |
Biocept
BIOC
|
-32 M | - | -13.05 % | $ 7.29 M | USA |
 |
Chembio Diagnostics
CEMI
|
-23.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
Check-Cap Ltd.
CHEK
|
-25.9 M | - | - | $ 9.42 M |  Israel |
 |
Co-Diagnostics
CODX
|
-50.2 M | $ 1.63 | -1.21 % | $ 2.17 M | USA |
 |
Castle Biosciences
CSTL
|
8.67 M | $ 24.7 | -1.12 % | $ 686 M | USA |
 |
CareDx, Inc
CDNA
|
-30.8 M | $ 21.91 | 0.27 % | $ 1.17 B | USA |
 |
DermTech
DMTK
|
-104 M | - | -11.32 % | $ 2.94 M | USA |
 |
Enzo Biochem
ENZ
|
-12.4 M | - | -8.98 % | $ 14.8 K | USA |
 |
Exact Sciences Corporation
EXAS
|
-206 M | - | - | $ 19.8 B | USA |
 |
Fulgent Genetics
FLGT
|
-73.9 M | $ 15.3 | -1.92 % | $ 463 M | USA |
 |
Global Cord Blood Corporation
CO
|
609 M | - | - | $ 399 M |  China |
 |
Genetron Holdings Limited
GTH
|
-518 M | - | 0.12 % | $ 80.1 M | China |
 |
Charles River Laboratories International
CRL
|
25.2 M | $ 166.79 | -2.59 % | $ 8.27 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
-20.8 M | - | -20.0 % | $ 1.06 M | USA |
 |
Guardant Health
GH
|
-437 M | $ 83.09 | -6.11 % | $ 10.4 B | USA |
 |
Koninklijke Philips N.V.
PHG
|
553 M | $ 27.12 | -1.53 % | $ 20 B |  Niderland |
 |
Illumina
ILMN
|
-833 M | $ 126.92 | -1.24 % | $ 20.2 B | USA |
 |
Heska Corporation
HSKA
|
-20.3 M | - | - | $ 1.31 B | USA |
 |
Interpace Biosciences
IDXG
|
4.08 M | $ 1.93 | - | $ 8.54 M | USA |
 |
Lantheus Holdings
LNTH
|
311 M | $ 83.55 | -0.67 % | $ 5.64 B | USA |
 |
QIAGEN N.V.
QGEN
|
466 M | - | - | $ 10.6 B | Niderland |
 |
Medpace Holdings
MEDP
|
535 M | $ 409.65 | -2.78 % | $ 11.8 B | USA |
 |
Biomerica
BMRA
|
-5.14 M | $ 2.19 | 0.46 % | $ 5.03 M | USA |
 |
Motus GI Holdings
MOTS
|
-11.9 M | - | -34.28 % | $ 263 K | Israel |
 |
ICON Public Limited Company
ICLR
|
1.1 B | $ 102.49 | -0.7 % | $ 8.45 B |  Irlanda |
 |
Laboratory Corporation of America Holdings
LH
|
1.38 B | $ 259.57 | -1.47 % | $ 21.6 B | USA |
 |
NeoGenomics
NEO
|
-116 M | $ 9.02 | 4.76 % | $ 1.16 B | USA |
 |
Celcuity
CELC
|
-172 M | $ 120.07 | -4.46 % | $ 5.61 B | USA |
 |
Neogen Corporation
NEOG
|
-1.06 B | $ 9.34 | -1.16 % | $ 2.03 B | USA |
 |
National Research Corporation
NRC
|
22.6 M | $ 16.84 | -1.58 % | $ 377 M | USA |
 |
Myriad Genetics
MYGN
|
-387 M | $ 4.84 | 0.21 % | $ 448 M | USA |
 |
Natera
NTRA
|
-541 M | $ 200.17 | -2.06 % | $ 19.7 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
1.56 B | $ 195.05 | -0.8 % | $ 21.7 B | USA |
 |
Invitae Corporation
NVTA
|
-94.9 M | - | - | $ 21.2 M | USA |
 |
OpGen
OPGN
|
325 K | - | -16.95 % | $ 1.54 M | USA |
 |
Organovo Holdings
ONVO
|
-12.6 M | - | -2.3 % | $ 19.4 M | USA |
 |
PerkinElmer
PKI
|
357 M | - | -0.91 % | $ 14.7 B | USA |
 |
Precipio
PRPO
|
-1.2 M | $ 31.75 | 3.42 % | $ 51 M | USA |
 |
Personalis
PSNL
|
-68.3 M | $ 5.5 | -7.72 % | $ 326 M | USA |
 |
Senseonics Holdings
SENS
|
-68.3 M | $ 7.18 | -1.24 % | $ 300 M | USA |
 |
Burning Rock Biotech Limited
BNR
|
-797 M | $ 16.65 | -12.64 % | $ 179 M | China |